Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Photoreceptors and Visual Pathways01:22

Photoreceptors and Visual Pathways

At the molecular level, visual signals trigger transformations in photopigment molecules, resulting in changes in the photoreceptor cell's membrane potential. The photon's energy level is denoted by its wavelength, with each specific wavelength of visible light associated with a distinct color. The spectral range of visible light, classified as electromagnetic radiation, spans from 380 to 720 nm. Electromagnetic radiation wavelengths exceeding 720 nm fall under the infrared category, whereas...
Focusing of Light in the Eye01:16

Focusing of Light in the Eye

Light rays enter the eye through the cornea, a transparent dome-shaped tissue that is the eye's outermost layer. The cornea bends or refracts, light rays traveling to the pupil. The shape of the cornea determines how much of the light is bent and whether the image will be focused correctly on the retina at the back of the eye. Once the light has passed through both refraction layers, it converges into a single focal point onto a small area. This is where photoreceptors start transforming...
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Remote Tonometry Identifies Significant Variability in the Timing of Intraocular Pressure Response to Topical Medication Change.

Ophthalmology. Glaucoma·2026
Same author

The internal limiting basement membrane inhibits functional engraftment of transplanted human retinal ganglion cells in vivo.

Science translational medicine·2026
Same author

Deep learning method for semi-automated segmentation of optic nerve head tissues in optical coherence tomography images.

Experimental eye research·2025
Same author

Crowd-Sourced Glaucoma Study. Definition of Glaucoma for Research by a Large Group of Global Expert Evaluators.

American journal of ophthalmology·2025
Same author

Cellular responses to short-term intraocular pressure elevation in a porcine eye explant model.

Experimental eye research·2025
Same author

Prevalence of Glaucoma in Europe and Projections to 2050: Findings from the European Eye Epidemiology Consortium.

Ophthalmology·2025
Same journal

Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective.

Lancet (London, England)·2026
Same journal

The US Ebola response and the future of global health leadership.

Lancet (London, England)·2026
Same journal

Daniel Mason: a tale of change.

Lancet (London, England)·2026
Same journal

The 2026 Wakley-Wu Lien Teh Prize Essay: why medicine, and why stay?

Lancet (London, England)·2026
Same journal

Indonesia's health reform: from pandemic mandate to the six pillars of transformation.

Lancet (London, England)·2026
Same journal

LGBTQ+ Russians increasingly avoiding doctors.

Lancet (London, England)·2026
See all related articles

Related Experiment Video

Updated: Jun 3, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

Glaucoma.

Harry A Quigley1

  • 1Glaucoma Service and Dana Center for Preventive Ophthalmology, Wilmer Ophthalmological Institute, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA. hquigley@jhmi.edu

Lancet (London, England)
|April 2, 2011
PubMed
Summary
This summary is machine-generated.

Glaucoma affects 60 million worldwide, often undiagnosed until vision loss is irreversible. Improved detection and novel treatments like gene therapy are crucial for managing this chronic eye disease.

More Related Videos

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis
13:47

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis

Published on: June 3, 2018

Related Experiment Videos

Last Updated: Jun 3, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis
13:47

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis

Published on: June 3, 2018

Area of Science:

  • Ophthalmology
  • Neuroscience

Background:

  • Glaucoma, encompassing open-angle and angle-closure forms, impacts millions globally, with significant visual function loss and bilateral blindness.
  • A substantial portion of glaucoma cases remain undiagnosed, even in developed nations, due to its asymptomatic nature in early stages.

Purpose of the Study:

  • Highlight the global burden of glaucoma and the urgent need for enhanced case-detection strategies.
  • Discuss current treatment challenges, including poor adherence to daily eye drops for this chronic condition.
  • Explore potential future therapeutic avenues, such as neuroprotective strategies and gene therapy, drawing parallels with central nervous system diseases.

Main Methods:

  • Review of population-based survey data to estimate glaucoma prevalence and impact.
  • Analysis of current treatment modalities and patient adherence issues.
  • Exploration of potential therapeutic strategies based on disease pathogenesis and advancements in other fields.

Main Results:

  • Glaucoma affects 1 in 40 adults over 40, totaling 60 million worldwide, with 8.4 million bilaterally blind.
  • Vision loss in glaucoma is irreversible, underscoring the need for early detection.
  • Current treatments face challenges with patient adherence, similar to other chronic systemic diseases.

Conclusions:

  • There is a critical need for improved methods to detect glaucoma earlier to prevent irreversible vision loss.
  • Future research may focus on neuroprotective agents and gene therapy, leveraging similarities with central nervous system disease pathogenesis and existing ocular gene therapies.